Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
acronym, adulterated, age, agreed, airflow, allergy, andElestatwill, andProlacria, andRestasisand, approveProlacria, artery, award, beneficiary, blended, Bulletin, burn, CABG, CAC, Canada, carcinogenicity, cardiac, Cardiology, channel, children, chose, closing, College, commercializeProlacria, commercializeProlacriaTM, coronary, coveringElestatwill, critical, deterioration, developingProlacria, digestive, diversification, economic, endpoint, enjoin, entity, equitable, eventProlacria, Expiratory, expressed, facilitate, factor, FAS, fee, flow, forElestatand, forElestatandRestasisbeginning, forfeiture, formulary, forProlacria, forProlacriaand, found, FSP, GmbH, graft, HHS, humor, hypertonic, identical, ifprolacria, inaccurate, incidence, Inclusion, IND, indirect, Inspector, intent, interaction, intervention, intranasal, intraocular, invariably, Japan, life, light, lowest, marketingElestat, marketingProlacria, measure, measured, measurement, measuring, median, Merck, meshwork, misbranded, mix, MMA, moderate, Modernization, monthly, morbidity, multiplied, mutation, mutual, negotiated, note, obstruction, ofElestatand, ofElestatandRestasisunder, ofElestathave, ofElestatin, ofProlacria, ofRestasiswhich, older, outflow, Overview, pathway, peer, pivotal, poorly, portable, pressure, promoteElestat, proportionate, protein, rebate, recruit, reevaluated, Registry, rehydration, reliability, requested, requisite, royalty, run, SAB, saline, school, seize, Seizing, sellElestat, sellingProlacria, shareholder, sicker, simplified, SinceProlacria, smaller, Social, sought, subregulatory, surface, synthesizing, table, temporary, term, thatProlacria, TIGER, toProlacria, trabecular, tradename, transmembrane, Treasury, unrecognized, unsuccessful, updated, violative, Winter, withProlacria
Removed:
accumulation, acquired, acuity, amortization, amounting, andAngiomax, andTOBI, artificial, assumption, bilateral, brand, Bush, calculated, caption, cataract, choroid, ciliary, clinically, colored, comparable, comprising, consultation, contractually, corneal, delivery, educated, epithelium, equipment, experimental, healing, historic, implement, improving, includePlavix, includePulmozyme, inflammatory, injection, inside, insufficient, intravitreal, investigating, keratectomy, lease, lining, LLC, maintenance, Mirco, myopic, occurred, ophthalmology, pathological, persistent, photorefractive, pigmented, pilot, PRK, punctal, relation, replacement, restate, retina, retrospective, situated, sponsoring, staining, Supplemental, sustained, thrombin, tissue, tract, Transaction, underneath, uveal, vascular, vision, visual, worth, wound
Filing tables
Filing exhibits
ISPH similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report of Inspire Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2006, as filed with the Securities and Exchange Commission (the “Report”), I, Christy L. Shaffer, President & Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| 1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Date: May 10, 2006 | /s/ Christy L. Shaffer | |
Christy L. Shaffer President & Chief Executive Officer (principal executive officer) |